Discover the trends and key figures for the 62 European biotechs* listed on the Euronext markets. At the end of the second half of 2020, 38 biotechs were listed in Paris, 10 in Brussels, 10 in Oslo, 3 in Amsterdam and 1 in Dublin, representing a combined market capitalisation of €29 billion.
Europe's leading listing venue, supporting biotechs during an unprecedented pandemic
A unique listing pool in Europe for Healthtechs, with record market capitalisation of €29.1bn (+€4.7bn over the year as a whole, a twofold increase on end 2018)
A health crisis but not a financial crisis: stock markets continued to play their role and in particular have allowed significant asset rotation in favor of healthcare stocks.
Liquidity at record levels: €194m traded on daily average across the 62 biotechs listed on Euronext (compared to a daily average of €99m over the last 3 years)
Robust fundraising activity: €62m in IPOs in H2 2020 (best half-year since H1 2018) and €2.7bn in secondary fundraising
A sector that has once again become an investment theme for equity asset managers
+218%: average annual performance of the Euronext BiotechBourse panel in 2020
+30%: the net number of institutional investors with positions on Euronext-listed Healthtechs reached 539 at the end of 2020 (vs. 420 at the end of 2019)
High turnover of the investor population: 288 incoming investors and 169 exiting investors during the year 2020
Total net investment flow in 2020: €737m (inflow of €1.67bn vs. outflow of €931m)
Positive news flow: reduced by the health crisis (which has slowed down the progress of clinical trials) but still contributing to the improvement of market sentiment. More positive announcements with an amplified impact on share prices.
2020, the year of Covid-19 for biotechs listed on Euronext
15 Healthtech members of the panel are working to combat Covid-19, either by providing diagnostic solutions (4), or by developing vaccines (2) or treatments (9).
Their share price rose by an average of +577.2% in 2020.
The market capitalisation of these "Covid Healthtech" companies totalled €4.2 billion at the end of 2020 (+€1.1 billion in June 2020), with investors particularly valuing vaccine companies in the second half of 2020.
*in the areas of Diagnostics and Therapeutics. List of companies available in the appendix (see link above). Data as at 30/11/2020.